Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    614 result(s) found for: Psoriasis. Displaying page 1 of 31.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-000943-17 Sponsor Protocol Number: NL54557.091.15 Start Date*: 2016-02-11
    Sponsor Name:Radboudumc
    Full Title: Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.
    Medical condition: Adult Patients diagnosed psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10015581 Exacerbation of psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037155 Psoriasis and similar disorders LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037156 Psoriasis flare-up LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010863-18 Sponsor Protocol Number: NL26548.101.09 Start Date*: 2010-06-25
    Sponsor Name:Amphia ziekenhuis
    Full Title: The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis: a prospective single blind unicenter randomized clinical trial
    Medical condition: Psoriasis patient getting UVB lighttherapy in a dermatological daycare center
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015581 Exacerbation of psoriasis LLT
    9.1 10037153 Psoriasis LLT
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000164-28 Sponsor Protocol Number: 8400-201 Start Date*: 2013-04-04
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050577 Psoriatic plaque LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003252-38 Sponsor Protocol Number: Hx-Inflam-302 Start Date*: 2006-09-01
    Sponsor Name:Genmab A/S
    Full Title: An open label clinical pilot study with local injection of human antibody (HuMax-Inflam) for the treatment of inflammatory psoriasis
    Medical condition: inflammatory psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004798-17 Sponsor Protocol Number: CAIN457F2301T Start Date*: 2015-05-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoria...
    Medical condition: Psoriasis or prosiatric arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037154 Psoriasis aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000571-13 Sponsor Protocol Number: VIC-PSO1 Start Date*: 2011-05-24
    Sponsor Name:Gentofte Hospital
    Full Title: The effect of GLP-1 in psoriasis
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004260-31 Sponsor Protocol Number: HUM-05-096 Start Date*: 2007-02-21
    Sponsor Name:UHL NHS Trust
    Full Title: An open label study of humira (adalimumab)in the treatment of patients with severe psoriasis
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014364-18 Sponsor Protocol Number: 579/09 Start Date*: 2009-10-01
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PSORIASIS AND CARDIOVASCULAR DISEASE: IMMUNOMODULATOR ROLE OF THE TREATMENT WITH ROSUVASTATIN IN PATIENTS WITH PSORIASIS OF MILD OR OF MODERATE-SEVERE SKIN DISEASE.
    Medical condition: PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007011-24 Sponsor Protocol Number: 1583 Start Date*: 2007-09-21
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Assessment of endothelial function in patients with psoriasis before and after Etanercept treatment
    Medical condition: moderate to severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037153 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003086-34 Sponsor Protocol Number: CAIN457A3301 Start Date*: 2013-12-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Ind...
    Medical condition: Moderate to severe chronic palmoplantar pustular psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037158 Psoriasis palm & soles LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002143-42 Sponsor Protocol Number: 16013 Start Date*: 2017-11-08
    Sponsor Name:Odense University Hospital
    Full Title: A designed Patient-centered Intervention to Improve medical Adherence in Topical Treatment of psoriasis - A Study protocol
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001556-67 Sponsor Protocol Number: derhill2017/1 Start Date*: 2017-05-17
    Sponsor Name:UZ Brussel
    Full Title: The effect of emollients on pruritus in psoriasis
    Medical condition: Psoriasis is traditionally considered a non-itchy skin disease. It seems that itch is an underestimated, and therefore undertreated aspect of psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002640-25 Sponsor Protocol Number: RR12/10234 Start Date*: 2013-02-07
    Sponsor Name:University of Leeds/Leeds Teaching Hospitals NHS Trust
    Full Title: A prospective, single-centre, feasibility study evaluating the prevalence of diagnostic clinical imaging features of subclinical enthesitis in patients with moderate to severe plaque psoriasis and ...
    Medical condition: Psoriatic disease (psoriasis and psoriatic arthritis).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10066579 Progression of psoriatic arthritis LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    14.1 100000004859 10037160 Psoriatic arthritis LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037157 Psoriasis of scalp LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10063407 Psoriasis genital LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10028703 Nail psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001568-12 Sponsor Protocol Number: 16-02/CalciBet-S Start Date*: 2016-10-18
    Sponsor Name:Dermapharm AG
    Full Title: A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared ...
    Medical condition: chronic stable plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004721-41 Sponsor Protocol Number: CHUBX 2008/08 Start Date*: 2008-10-07
    Sponsor Name:CHU de Bordeaux
    Full Title: Profil des populations leucocytaires chez les patients atteints de psoriasis répondeurs et non répondeurs au traitement par efaluzimab (anti-CD11A) : étude systémique et cutanée
    Medical condition: patients atteints de psoriasis modérés à sévère
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002588-40 Sponsor Protocol Number: CAIN457ADE02T Start Date*: 2016-05-31
    Sponsor Name:University Hospital Schleswig-Holstein
    Full Title: Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients
    Medical condition: moderate-to-severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005518-29 Sponsor Protocol Number: 08F/BET01 Start Date*: 2008-12-01
    Sponsor Name:Laboratoires GENEVRIER
    Full Title: An exploratory, open-label, intra-individual,active- controlled study comparing the efficacy and safety of Betesil versus Daivobet for the treatment of chronic plaque psoriasis
    Medical condition: Chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000710-53 Sponsor Protocol Number: RD.06.SPR.18131 Start Date*: 2014-12-19
    Sponsor Name:GALDERMA R&D, LLC
    Full Title: A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months o...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-007678-43 Sponsor Protocol Number: P070602 Start Date*: 2008-04-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation de l'efficacité et de la tolérance de deux stratégies de prescription du Méthotrexate dans le traitement du psoriasis
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002738-39 Sponsor Protocol Number: 04-7-011 Start Date*: 2006-09-22
    Sponsor Name:Astelleas Pharma US, Inc.
    Full Title: A Phase 1 Open-Label Study of the Pharmacokinetics of Tacrolimus Cream B 0.1% after Twice Daily Topical Administration in Adolescents (≥ 12 to ≤ 17 Years of Age ) with Psoriasis
    Medical condition: Determination of pharmacokinetics and safety of tacrolimus in adolescents with plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 11:01:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA